Why we should not recommend or offer fluvoxamine to COVID-19 patients?
Crossref DOI link: https://doi.org/10.1007/s00228-022-03447-3
Published Online: 2022-12-23
Published Print: 2023-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Trkulja, Vladimir
Text and Data Mining valid from 2022-12-23
Version of Record valid from 2022-12-23
Article History
Received: 29 October 2022
Accepted: 18 December 2022
First Online: 23 December 2022
Declarations
:
: The author declares no competing interests.
Free to read: This content has been made available to all.